<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01215734</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BMT 1057</org_study_id>
    <secondary_id>100980</secondary_id>
    <secondary_id>100980</secondary_id>
    <nct_id>NCT01215734</nct_id>
  </id_info>
  <brief_title>Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients</brief_title>
  <official_title>Randomized Double-Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine Versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Stem Cell Hematopoetic Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis 1: The safety profile in adult allogeneic stem cell hematopoietic transplant
      (SCT) recipients after high dose (HD) trivalent inactivated influenza vaccine (TIV) will not
      be significantly different from adult stem cell transplant recipients receiving standard
      dose (SD) TIV.

        -  Specific Aim 1: To compare safety profile of high dose trivalent inactivated influenza
           vaccine to standard dose trivalent inactivated influenza vaccine in adult hematopoietic
           stem cell transplant recipients.

      Hypothesis 2: Adult stem cell transplant recipients who received the higher dose trivalent
      influenza vaccine will have a greater frequency of (at least a 4-fold) rise in antibody
      titers to influenza antigens compared to those who receive standard dose trivalent influenza
      vaccine.

        -  Specific Aim 2: To compare humoral immune responses of adult hematopoietic stem cell
           transplant recipients influenza virus antigens included in trivalent influenza vaccine
           after high dose or standard dose trivalent influenza vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator), Primary Purpose:  Prevention</study_design>
  <primary_outcome>
    <measure>To compare safety profile of high dose (HD) trivalent influenza vaccine (TIV)to standard dose (SD) trivalent influenza vaccine in adult hematopoetic stem cell transplant (SCT) recipients</measure>
    <time_frame>Prior to TIV and 28-35 days after TIV</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare humoral immune responses of adult hematopoietic SCT recipients influenza virus antigens included in TIV after HD or SD-TIV.</measure>
    <time_frame>6-9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Adult Stem Cell Hematopoetic Transplant</condition>
  <arm_group>
    <arm_group_label>High-Dose Trivalent Inactivated Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Forty adult hematopoetic stem cell transplant recipients at least 6 months post transplant will receive high dose trivalent influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose Trivalent Inactivated Flu Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twenty Adult stem cell transplant recipients at least 6 months post transplant will receive standard dose trivalent influenza vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)</intervention_name>
    <description>0.5 ml of HD-TIV on visit 1</description>
    <arm_group_label>High-Dose Trivalent Inactivated Influenza Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard Dose Trivalent Inactivated Flu Vaccine</intervention_name>
    <description>Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.</description>
    <arm_group_label>Standard dose Trivalent Inactivated Flu Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allogeneic hematopoietic stem cell transplant recipients who are &gt;6 post-transplant

          -  greater than or equal to 18 years of age

          -  Available for duration of study

          -  If patients are on immunosuppressive therapy for treatment of graft versus host
             disease (GVHD): only those on stable doses for at least 4 weeks or on tapering doses
             will be eligible.

        Exclusion Criteria:

          -  History of hypersensitivity to previous influenza vaccination or hypersensitivity to
             eggs/egg protein

          -  History of Guillain-Barre syndrome

          -  Evidence of hematologic malignancy or disease relapse post-transplant (mixed
             chimerisms and molecular evidence of disease is permitted)

          -  Non-allogeneic (e.g. autologous) hematopoietic SCT recipients

          -  History of receiving 2011 - 2012 influenza vaccine

          -  History of proven influenza disease after September 1, 2011.

          -  Pregnant females

          -  Have any condition that would, in the opinion of the site investigator, place them at
             an unacceptable risk of injury or render them unable to meet the requirements of the
             protocol

          -  Have any condition that the investigator believes may interfere with successful
             completion of the study

          -  Platelet count less than 50,000 cells/Î¼L

          -  History of known infection with HIV, Hepatitis B or Hepatitis C

          -  History of known latex hypersensitivity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha Halasa, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VICC Clinical Trials Information Program</last_name>
    <phone>800-811-8480</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center, Clinical Trials Information Program</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Reporting Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Natasha Halasa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 17, 2011</lastchanged_date>
  <firstreceived_date>October 5, 2010</firstreceived_date>
  <responsible_party>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
</clinical_study>
